Actively Recruiting
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
Led by Crinetics Pharmaceuticals Inc. · Updated on 2025-04-10
18
Participants Needed
1
Research Sites
155 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A Phase 1b/2a, first-in-disease, open-label, multiple-ascending dose exploratory study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamic biomarker responses associated with CRN04894 (an adrenocorticotropic hormone \[ACTH\] receptor antagonist) in participants with ACTH-dependent Cushing's syndrome (Cushing's disease or Ectopic ACTH Syndrome \[EAS\])
CONDITIONS
Official Title
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult male or female, aged 18 years or more
- Evidence of chronic 'active' ACTH-dependent Cushing's syndrome
- Evidence of acutely 'active' ACTH-dependent Cushing's syndrome within 10 days of Day 1
- Participants taking short-acting steroidogenesis inhibitors (ketoconazole, levoketoconazole, osilodrostat, or metyrapone) may participate after at least 5 days washout, if eligible
- Participants taking cabergoline may participate after at least 14 days washout, if eligible
You will not qualify if you...
- Women who are pregnant or lactating
- History of bilateral adrenalectomy
- Previous pituitary MRI showing ACTH-secreting lesion within 3 mm of optic chiasm
- Presence of any known malignancy
- Use of mitotane
- Previous unsuccessful surgery for Cushing's syndrome within 6 weeks
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Institutes of Health (NIH) - National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Bethesda, Maryland, United States, 20892
Actively Recruiting
Research Team
C
Crinetics Clinical Trials
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here